安徽山河药用辅料股份有限公司 特定对象来企调研会议纪要 【会议时间】 ：2018 年 7 月 19 日 13:30-16:30 【会议地点】 ：安徽省淮南市经济技术开发区河滨路 2 号公司四楼会议室 | --- | --- | |-----------------------------|-------| | | | | ：山河药辅董事会秘书 胡浩 | | | 山河药辅证券事务代表 朱睿 | | | | | | 山河药辅证券事务主管 姜之舟 | | | | | | 浙商证券 陈亚天 | | 【出席人员】 杭州昌渝投资 石维坚 【调研内容】 1.一致性评价对公司的影响 关联审评以后一旦通过，如制剂企业要更换辅料供应商预计需要重新做包括溶出 度曲线在内的所有临床前试验（国家相关政策正在拟定中），成本相对较高。一致性 评价对于龙头辅料企业有利好作用，如果最后只剩下三家企业做一个仿制药产品，那 小辅料企业也将面临淘汰，行业集中度显著提升，公司产品相比与其他企业竞争优势 主要还是在质量和品牌上。 预计下半年或明年年初开始一致性评价带来的量增宏利会逐步释放。 2.公司产能状况 公司辅料产品和同类型外资企业产品效果接近一致 ...

安徽山河药用辅料股份有限公司 特定对象来企调研会议纪要 【会议时间】 ：2018 年 11 月 23 日 9:30-12:00 【会议地点】 ：安徽省淮南市经济技术开发区河滨路 2 号公司四楼会议室 | --- | --- | |-----------------------------|-------| | | | | ：山河药辅董事会秘书 胡浩 | | | 山河药辅证券事务主管 姜之舟 | | | | | | 方正富邦基金 王喆 | | | 南华基金 徐顺利 | | | 中国人寿 张树声 | | | 域秀资本 涂翡斐 | | 【出席人员】 兴业证券 杜向阳 【调研内容】 1.公司简介 公司成立于 2001 年，山河药辅是从制药厂的辅料车间发展过来的，专门 做各种固体制剂药用辅料，一开始只有 5 个品种，现在发展到 26 个。目前国内 知名专业口服固体制剂药用辅料生产企业；国际药用辅料协会会员单位。公司主 要产品涵盖填充剂、黏合剂、崩解剂、润滑剂、包衣材料等常用口服固体制剂类药 用辅料，主要产品有微晶纤维素、羟丙纤维素、羧甲淀粉钠、硬脂酸镁、羟丙甲纤 维素、交联聚维酮等。公司客户 90%以上都是药企。员工近 ...

安徽山河药用辅料股份有限公司 特定对象来企调研会议纪要 【会议时间】 ：2018 年 10 月 31 日 13:30-16:30 【会议地点】 ：安徽省淮南市经济技术开发区河滨路 2 号公司四楼会议室 【出席人员】 ：山河药辅董事会秘书 胡浩 山河药辅证券事务代表 朱睿 山河药辅证券事务主管 姜之舟 中银国际证券 邓周宇 中银国际证券 高睿婷 【调研内容】 1.一致性评价对公司的影响和进展 一致性评价中的药用辅料与药品关联审评，需要做包括溶出度曲线在内的 临床前试验，保证溶出曲线、稳定性以及后续疗效一致，其中辅料的质量特性起 到了重要作用；如果制药企业只选择一家辅料企业产品，这对龙头辅料企业是 利好作用，我公司作为固体制剂药用辅料龙头企业，所以一致性评价政策的推 行有利于公司的发展；据初步统计，目前通过一致性评价的制药企业有一半以 上使用了我公司的辅料产品，预计一致性评价政策带来的量增红利会逐步释放。 2. 公司目前的产能状况 公司募投资金建设二期项目年底即将投产，以缓解目前公司主要产品产能 不足的状况；目前微晶纤维素满产，募投一期项目 2500 吨已投产，二期项目 建成后产能将达到 7000 吨以上，羧甲淀 ...

投资者关系活动记录表 证券代码：300452 证券简称：山河药辅 编号：2021-001 | --- | --- | --- | |------------------------|-------------------------------------------------------|-----------------------------------------------------------------------------| | | | | | | 特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 | 路演活动 | | | 现场参观 | | | | 其他 电话交流会 | | | 参与单位名称及人员姓名 | 【嘉实基金】：颜媛，牛歌 | | | 时间 | 2021 年 2 月 24 日 10 ： | 30-11 ： 30 | | | | | | 上市公司接待人员姓名 | 董事、副总经理、董事会秘书：胡浩 证券事务代表：姜之舟 | | | | 问题 1 | ：公司目前的经营情况如何？ 回答：公司近期生产经营势头良好，产销两 ...

投资者关系活动记录表 编号：2021-004 证券代码：300452 证券简称：山河药辅 安徽山河药用辅料股份有限公司投资者关系活动记录表 | --- | --- | --- | |------------------------|------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | ...

投资者关系活动记录表 编号：2021-005 证券代码：300452 证券简称：山河药辅 安徽山河药用辅料股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | ...

投资者关系活动记录表 证券代码：300452 证券简称：山河药辅 安徽山河药用辅料股份有限公司 投资者关系活动记录表 编号：2022-001 | --- | --- | --- | |-----------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

投资者关系活动记录表 编号：2022-002 证券代码：300452 证券简称：山河药辅 安徽山河药用辅料股份有限公司投资者关系活动记录表 | --- | --- | --- | |------------------------|--------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | √其他（ ...

投资者关系活动记录表 证券代码：300452 证券简称：山河药辅 安徽山河药用辅料股份有限公司投资者关系活动记录表 编号：2022-003 | --- | --- | --- | |------------------------|-----------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Financial Performance - The company's revenue for Q3 2022 reached ¥165,215,292.43, representing a year-on-year increase of 17.41%[4] - Net profit attributable to shareholders for Q3 2022 was ¥28,468,579.65, up 47.69% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥25,347,762.22, reflecting a 60.89% increase year-on-year[4] - The company reported a significant improvement in profitability, with a net profit growth of 47.69% in Q3 2022 compared to the same quarter last year[7] - The net profit for the third quarter of 2022 was CNY 93,461,300.05, an increase of 31.9% compared to CNY 70,859,435.00 in the same period last year[24] - The operating profit for the quarter was CNY 105,348,970.98, up from CNY 81,980,101.56, reflecting a growth of 28.5% year-over-year[24] - The total revenue from operating activities was CNY 440,694,713.22, compared to CNY 369,585,368.55 in the previous year, indicating an increase of 19.2%[26] - The company reported a total comprehensive income of CNY 93,461,300.05, compared to CNY 70,859,435.00 in the previous year, marking a growth of 31.9%[25] - Basic and diluted earnings per share for the quarter were both CNY 0.40, up from CNY 0.31 in the same period last year, representing a growth of 29.0%[25] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥1,037,580,019.65, an increase of 7.79% from the end of the previous year[4] - Current assets totaled ¥571,326,276.68, a rise of 3.9% from ¥552,823,876.60 at the start of the year[20] - The total liabilities increased to ¥292,120,152.63, compared to ¥256,665,812.73 at the beginning of the year, marking a rise of 13.7%[21] - The equity attributable to the parent company reached ¥680,767,283.21, an increase from ¥640,000,201.75, reflecting a growth of 6.4%[21] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥57,097,827.18, up 52.67% year-on-year, primarily due to increased cash receipts from sales[11] - The cash flow from operating activities generated a net amount of CNY 57,097,827.18, which is a 52.7% increase from CNY 37,398,682.03 in the same quarter last year[26] - The company's cash and cash equivalents at the end of the reporting period were ¥83,437,400, reflecting a 30.97% increase year-on-year[11] - The cash and cash equivalents at the end of the period were CNY 83,437,409.98, an increase from CNY 63,709,279.69 at the end of the previous year[27] - The net cash flow from investing activities was negative at CNY -42,031,724.76, worsening from CNY -13,309,878.48 in the same quarter last year[27] - The total cash outflow from financing activities was CNY 92,676,991.49, slightly higher than CNY 91,783,425.39 in the same period last year[27] Research and Development - Research and development expenses for the year-to-date period amounted to ¥24,076,800, representing a 46.98% increase year-on-year due to increased R&D investment[10] - Research and development expenses increased significantly to ¥24,076,821.87, compared to ¥16,381,375.50 in the previous period, reflecting a growth of 47.0%[22] - The company has continued to focus on R&D innovation and customer import substitution to achieve steady performance growth despite external challenges[7] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,281[13] - The largest shareholder, Yin Zhenglong, holds 26.89% of shares, totaling 63,057,454 shares[13] - Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. holds 11.19% of shares, totaling 26,254,059 shares[13] - Liu Tao, a natural person, holds 3.13% of shares, totaling 7,329,343 shares[14] - The total number of restricted shares held by Yin Zhenglong is 47,293,089, with no shares released during the period[16] - The total number of restricted shares at the end of the period is 48,490,334[17] - The company has a total of 90 natural person shareholders with restricted shares totaling 852,540[17] - The company has not reported any changes in the number of preferred shareholders[15] Other Information - The company has not disclosed any new product or technology developments in this report[18] - There are no significant mergers or acquisitions reported in this quarter[18]